At­las-in­cu­bat­ed Kymera leaps out of stealth mode, joins the hunt for game-chang­ing pro­tein degra­da­tion drugs

Pro­tein degra­da­tion R&D isn’t new. Jay Brad­ner launched C4 Ther­a­peu­tics to blaze the pro­tein degra­da­tion ap­proach just be­fore he took the helm at the No­var­tis In­sti­tute of Bio­med­ical Re­search, then re­cent­ly formed a dis­cov­ery al­liance with UC Berke­ley with the same ba­sic ap­proach in mind. Arv­inas al­so has cen­tered on pro­tein degra­da­tion, build­ing on the lab work of Yale’s Craig Crews.

But to­day there’s an­oth­er start­up join­ing the pi­o­neers called Kymera, and the Cam­bridge, MA-based play­er is com­ing out of stealth mode to­day with a $30 mil­lion launch round and a de­vel­op­ment strat­e­gy cre­at­ed on the no­tion that there’s plen­ty of vir­gin ter­ri­to­ry for every­one to ex­plore.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER